Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCRIT in Cancer-Associated Anemia Without Chemotherapy
NCT00306267Phase 2Terminated
- Sponsor
- Johnson & Johnson
- Start
- Mar 2006
01
Overview
Phase 2, randomised, open-label trial of epoetin alfa in anemia (2 arms), sponsored by Johnson & Johnson. Primary endpoint: Hematopoietic response at 13 weeks. Started Mar 2006; status: terminated.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00306267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00306267.